Iran as the Center of challenges in the Middle East for the Outbreak of COVID-19 Delta Variant


Delta variant
Middle East
Political sanctions
Pulmonary disease

How to Cite

Shakibnia, P. ., Heidari Ahmadi, R., Fallah, F., Ebrahimzadeh, F., Sadeghi Dosari, A. ., Mojtahedi, A. ., Hajipour, N. ., Sharifi Luyeh, M., & Taati Moghadam, M. (2021). Iran as the Center of challenges in the Middle East for the Outbreak of COVID-19 Delta Variant. Iranian Red Crescent Medical Journal, 23(11).


Context: During the past three decades, the Middle East has experienced three major viral epidemics. Coronavirus disease 2019 (COVID-19) is a pulmonary disease which has been first reported in China in the early third decade of the 21st century and quickly infected people in Asia, the Middle East, and the entire world. This pandemic is life-threatening and has caused widespread financial losses; however, the exact extent of the damage is still unclear.

Evidence Acquisition: This review study aimed to present the latest on the COVID-19 symptoms, pathogenicity, host immune responses, etiology and epidemiology, transmission routes in the Middle Eastern countries, especially Iran, and the role this country plays in the spread of the disease. The search was conducted using Google scholar, PubMed, Scopus, and ISI Web of Science to identify relevant studies published from 2019 to 2021.

Results: Many countries do not have sufficient equipment to prevent, identify, and treat the disease and still have major challenges in controlling this deadly virus. In Iran, a Middle Eastern country, people faced widespread disease and deaths due to the lack of facilities caused by heavy economic and political sanctions. These challenges affect not only Iran but also many neighboring countries. Over time, mutations in the SARS-CoV-2 virus led to the emergence of various variants of the virus, such as Alpha (B.1.1.7), Beta (B.1.351), Gamma (B., and Delta (B.1.617.2).

Conclusion: Different variants of SARS-CoV-2 virus pose a substantial menace to public health due to their high transmissibility and ability to escape the immune system. Recently, concerns have increased about the risk of hospitalization and the high spread rate of the COVID-19 delta variant.


  1. Organization WH. Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases: interim guidance, 2 March 2020. World Health Organization, 2020.
  2. Yavarian J, Rezaei F, Shadab A, Soroush M, Gooya MM, Azad TM. Cluster of Middle East respiratory syndrome coronavirus infections in Iran, 2014. Emerg Infect Dis.  2015;21(2):362.doi:  10.3201/eid2102.141405. PMID: 25626079.
  3. WHO. Novel Coronaries (2019-Nov) situation report - 55. 2020.
  4. Dousari AS, Moghadam MT, Satarzadeh N. COVID-19 (Coronavirus disease 2019): a new coronavirus disease. Infect Drug Resist.. 2020;13:2819.doi: 10.2147/IDR.S259279. PMID: 32848431
  5. Moghadam M, Babakhani S, Rajabi S, Baravati F, Raeisi M, Dousari A,et al. Does Stress and Anxiety Contribute to COVID-19?. Iranian Journal of Psychiatry and Behavioral Sciences. 2021:2.doi: 10.5812/ijpbs.106041.
  6. Organization WH. Coronavirus disease 2019 (COVID-19) Situation Report 12, 30th January 2020. 2020.
  7. Moghadam MT, Taati B, Paydar Ardakani SM, Suzuki K. Ramadan fasting during the COVID-19 pandemic; observance of health, nutrition and exercise criteria for improving the immune system. Front Nutr. 2021;7:349.doi: 10.3389/fnut.2020.570235.
  8. Zhuang Z, Zhao S, Lin Q, Cao P, Lou Y, Yang L, et al. Preliminary estimation of the novel coronavirus disease (COVID-19) cases in Iran: a modelling analysis based on overseas cases and air travel data. Int J Infect Dis. 2020.doi:  10.1016/j.ijid.2020.04.073. PMID: 32360940.
  9. Dyer O. Covid-19: Indonesia becomes Asia’s new pandemic epicentre as delta variant spreads.BMJ; 2021.doi:
  10. Sahin AR, Erdogan A, Agaoglu PM, Dineri Y, Cakirci AY, Senel ME, et al. 2019 Novel Coronavirus (COVID-19) Outbreak: A Review of the Current Literature. EJMO. 2020;4(1):1-7.
  11. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. N Engl J Med. 2020.doi: 10.1056/NEJMoa2001316
  12. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395(10223):497-506.doi: 10.1016/S0140-6736(20)30183-5
  13. Chan JF-W, Yuan S, Kok K-H, To KK-W, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. The Lancet. 2020;395(10223):514-23.doi: 10.1016/S0140-6736(20)30154-9
  14. Carlos WG, Dela Cruz CS, Cao B, Pasnick S, Jamil S. Novel wuhan (2019-nCoV) coronavirus. Am J Respir Crit Care Med. 2020;201(4).doi: 10.1164/rccm.2014P7 . PMID: 32004066.
  15. Wang W, Tang J, Wei F. Updated understanding of the outbreak of 2019 novel coronavirus (2019‐nCoV) in Wuhan, China. J Med Virol.. 2020;92(4):441-7.doi: 10.1002/jmv.25689. PMID: 31994742.
  16. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet. 2020;395(10223):507-13.doi: 10.1016/S0140-6736(20)30211-7
  17. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, Villamizar-Peña R, Holguin-Rivera Y, Escalera-Antezana JP, et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis. 2020;34:101623.doi: 10.1016/j.tmaid.2020.101623 . PMID: 32179124.
  18. Lei J, Li J, Li X, Qi X. CT imaging of the 2019 novel coronavirus (2019-nCoV) pneumonia. Radiology 2020;295(1):18200236.doi: 10.1148/radiol.2020200236 . PMID: 32003646
  19. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun 2020;109:102433.doi: 10.1016/j.jaut.2020.102433 . PMID: 32113704
  20. Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet. 2020;395(10223):470-3.doi: 10.1016/S0140-6736(20)30185-9.PMID: 31986257.
  21. Hellewell J, Abbott S, Gimma A, Bosse NI, Jarvis CI, Russell TW, et al. Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts. Lancet Glob Health . 2020.doi: 10.1016/S2214-109X(20)30074-7 . PMID: 32119825.
  22. Hu Z, Song C, Xu C, Jin G, Chen Y, Xu X, et al. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. Sci China Life Sci. 2020:1-6.doi: 10.1007/s11427-020-1661-4. PMID: 32146694.
  23. Lüers J-C, Klußmann JP, Guntinas-Lichius O. Die Covid-19-Pandemie und das HNO-Fachgebiet: Worauf kommt es aktuell an?. Laryngo-Rhino-Otol. 2020.doi: 10.1055/a-1095-2344.
  24. Burki TK. Lifting of COVID-19 restrictions in the UK and the Delta variant. The LancetRespiratoryMedicine.2021;397:2461-62.doi:10.1016/S2213-2600(21)00328-3.
  25. Zhang M, Xiao J, Deng A, Zhang Y, Zhuang Y, Hu T, et al. Transmission Dynamics of an Outbreak of the COVID-19 Delta Variant B. 1.617. 2—Guangdong Province, China, May–June 2021. China CDC Weekly. 2021;3(27):584-6.
  26. Zhou D, Zhang P, Bao C, Zhang Y, Zhu N. Emerging Understanding of Etiology and Epidemiology of the Novel Coronavirus (COVID-19) infection in Wuhan, China. Preprints.  2020.doi: 10.20944/preprints202002.0283.v1.
  27. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The Lancet. 2020;395(10224):565-74.doi: 10.1016/S0140-6736(20)30251-8. PMID: 32007145.
  28. Wu F, Zhao S, Yu B, Chen Y-M, Wang W, Song Z-G, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265-9.
  29. Chen Y, Liu Q, Guo D. Emerging coronaviruses: genome structure, replication, and pathogenesis. J Med Virol . 2020.doi: 10.1002/jmv.25681. Epub 2020 Feb 7. PMID: 31967327.
  30. Ceraolo C, Giorgi FM. Genomic variance of the 2019‐nCoV coronavirus. J Med Virol . 2020.doi: 10.1002/jmv.25700. PMID: 32027036.
  31. National Health Commission of the people's Republic of China, Medicine NAoTC. Handbook of Prevention and Treatment of the Pneumonia Caused by the Novel Coronavirus (2019‐nCoV) (Trial version 5).
  32. Lai C-C, Shih T-P, Ko W-C, Tang H-J, Hsueh P-R. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and corona virus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents. 2020:105924.doi: 10.1016/j.ijantimicag.2020.105924 . PMID: 32081636.
  33. Organization WH. Water, sanitation, hygiene and waste management for COVID-19: technical brief, 03 March 2020. World Health Organization, 2020.
  34. Hoffmann M, Kleine-Weber H, Krüger N, Mueller MA, Drosten C, Pöhlmann S,et al. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. BioRxiv. 2020.doi: 10.1101/2020.01.31.929042 .
  35. Zhang H, Kang Z, Gong H, Xu D, Wang J, Li Z, et al. The digestive system is a potential route of 2019-nCov infection: a bioinformatics analysis based on single-cell transcriptomes. BioRxiv. 2020.doi: :10.1101/2020.01.30.927806.
  36. Yin Y, Wunderink RG. MERS, SARS and other coronaviruses as causes of pneumonia. Respirology. 2018;23(2):130-7.doi: 10.1111/resp.13196 . PMID: 29052924.
  37. World Helath Organization, 2019- nCoV Situation Report-22on 12 February, 2020.
  38. Gralinski LE, Menachery VD. Return of the Coronavirus: 2019-nCoV. Viruses. 2020;12(2):135.doi: 10.3390/v12020135. PMID: 31991541.
  39. ting the potential total number of novel Coronavirus cases in Wuhan City, China. Imperial College London. 2020.
  40. Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x, et al. Clinical characteristics of 2019 novel coronavirus infection in China. MedRxiv. 2020.doi: 10.1056/NEJMoa2002032 . PMID: 32109013.
  41. Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, Evaluation and Treatment Coronavirus (COVID-19).  StatPearls [Internet]: StatPearls Publishing. 2020. PMID: 32150360.
  42. Phan LT, Nguyen TV, Luong QC, Nguyen TV, Nguyen HT, Le HQ, et al. Importation and human-to-human transmission of a novel coronavirus in Vietnam. N Engl J Med . 2020;382(9):872-4.doi: 10.1056/NEJMc2001272 . PMID: 31991079.
  43. Chen Z, Zhang W, Lu Y, Guo C, Guo Z, Liao C, et al. From SARS-CoV to Wuhan 2019-nCoV outbreak: similarity of early epidemic and prediction of future trends. Cell Host & Microbe . 2020.
  44. Pulliam JR, Epstein JH, Dushoff J, Rahman SA, Bunning M, Jamaluddin AA, et al. Agricultural intensification, priming for persistence and the emergence of Nipah virus: a lethal bat-borne zoonosis. J R Soc Interface . 2012;9(66):89-101.doi: 10.1098/rsif.2011.0223 . PMID: 21632614.
  45. Millán-Oñate J, Rodriguez-Morales AJ, Camacho-Moreno G, Mendoza-Ramírez H, Rodríguez-Sabogal IA, Álvarez-Moreno C,et al. A new emerging zoonotic virus of concern: the 2019 novel Coronavirus (COVID-19). Infectio. 2020;24(3).doi: 10.22354/in.v24i3.848.
  46. Organization WH. Novel coronavirus (2019-nCoV)-situation report-10-30 January 2020. 2020.
  47. Yadav PD, Sapkal GN, Ella R, Sahay RR, Nyayanit DA, Patil DY, et al. Neutralization of Beta and Delta variant with sera of COVID-19 recovered cases and vaccinees of inactivated COVID-19 vaccine BBV152/Covaxin. Journal of Travel Medicine. 2021.doi: 10.1093/jtm/taab104.
  48. Lustig Y, Zuckerman N, Nemet I, Atari N, Kliker L, Regev-Yochay G, et al. Neutralising capacity against Delta (B. 1.617. 2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel. Euro Surveill . 2021;26(26):2100557.doi: 10.2807/1560-7917.ES.2021.26.26.2100557 . PMID: 34212838.
  49. Kirola L. Genetic emergence of B. 1.617. 2 in COVID-19. New Microbes and New Infections. 2021;43:100929.doi: 10.1016/j.nmni.2021.100929.
  50. Moona AA, Daria S, Asaduzzaman M, Islam MR. Bangladesh reported delta variant of coronavirus among its citizen: Actionable items to tackle the potential massive third wave. Infect Prev Pract. 2021;3(3):100159.doi: 10.1016%2Fj.infpip.2021.100159. PMID: 34316588.
  51. Dougherty K, Mannell M, Naqvi O, Matson D, Stone J. SARS-CoV-2 B. 1.617. 2 (Delta) variant COVID-19 outbreak associated with a gymnastics facility—Oklahoma, April–May 2021. Weekly. 2021;70(28):1004-1007.
  52. Ji W, Wang W, Zhao X, Zai J, Li X. Homologous recombination within the spike glycoprotein of the newly identified coronavirus may boost cross-species transmission from snake to human. J Med Virol. 2020.
  53. Zhang T, Wu Q, Zhang Z. Probable Pangolin Origin of SARS-CoV-2 Associated with the COVID-19 Outbreak. Curr Biol. 2020;30(7):1346-1351.doi: 10.1016/j.cub.2020.03.022 . PMID: 32197085.
  54. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by the novel coronavirus from wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J Virol . 2020;94(7).doi: 10.1128/JVI.00127-20 . PMID: 31996437.
  55. Coronavirinae in ViralZone. Available online: (accessed on 05 February 2019).
  56. Subissi L, Posthuma CC, Collet A, Zevenhoven-Dobbe JC, Gorbalenya AE, Decroly E, et al. One severe acute respiratory syndrome coronavirus protein complex integrates processive RNA polymerase and exonuclease activities. Proc Natl Acad Sci U S A. 2014;111(37):E3900-E9.doi: 10.1073/pnas.1323705111. PMID: 25197083.
  57. Chen X, Shang Y, Yao S, Liu R, Liu H. Perioperative care provider’s considerations in managing patients with the COVID-19 infections. Transl Perioper Pain Med. 2020;7:216-24.
  58. Wu P, Hao X, Lau EH, Wong JY, Leung KS, Wu JT, et al. Real-time tentative assessment of the epidemiological characteristics of novel coronavirus infections in Wuhan, China, as at 22 January 2020. Euro Surveill . 2020;25(3).doi: 10.2807/1560-7917.ES.2020.25.3.2000044. PMID: 31992388.
  59. Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. The Lancet. 2020;395(10226):809-15.doi: 10.1016/S0140-6736(20)30360-3.
  60. Mahase E. Delta variant: What is happening with transmission, hospital admissions, and restrictions?.BMJ . 2021.doi: 10.1136/bmj.n1513 .
  61. Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal . 2020;10(2):102-108.doi: 10.1016/j.jpha.2020.03.001. PMID: 32282863.
  62. de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol . 2016;14(8):523.doi: 10.1038/nrmicro.2016.81 . PMID: 27344959.
  63. Simmons G, Reeves JD, Rennekamp AJ, Amberg SM, Piefer AJ, Bates P. Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry. Proc Natl Acad Sci U S A . 2004;101(12):4240-5.doi: 10.1073/pnas.0306446101 . PMID: 15010527.
  64. Belouzard S, Chu VC, Whittaker GR. Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites.Proc Natl Acad Sci U S A . 2009;106(14):5871-6.doi: 10.1073/pnas.0809524106 . PMID: 19321428.
  65. Wang H, Yang P, Liu K, Guo F, Zhang Y, Zhang G, et al. SARS coronavirus entry into host cells through a novel clathrin-and caveolae-independent endocytic pathway. Cell Res. 2008;18(2):290-301.doi: 10.1038/cr.2008.15. PMID: 18227861.
  66. Kuba K, Imai Y, Ohto-Nakanishi T, Penninger JM. Trilogy of ACE2: A peptidase in the renin–angiotensin system, a SARS receptor, and a partner for amino acid transporters. Pharmacol Ther . 2010;128(1):119-28.doi: 10.1016/j.pharmthera.2010.06.003 . PMID: 20599443.
  67. Perlman S, Netland J. Coronaviruses post-SARS: update on replication and pathogenesis. Nat Rev Microbiol . 2009;7(6):439-50.doi: 10.1038/nrmicro2147 . PMID: 19430490.
  68. Liu J, Wu P, Gao F, Qi J, Kawana-Tachikawa A, Xie J, et al. Novel immunodominant peptide presentation strategy: a featured HLA-A* 2402-restricted cytotoxic T-lymphocyte epitope stabilized by intrachain hydrogen bonds from severe acute respiratory syndrome coronavirus nucleocapsid protein. J Virol . 2010;84(22):11849-57.doi: 10.1128/JVI.01464-10. PMID: 20844028.
  69. Li G, Chen X, Xu A. Profile of specific antibodies to the SARS-associated coronavirus. N Engl J Med . 2003;349(5):508-9.doi; 10.1056/NEJM200307313490520. PMID: 12890855.
  70. Fan Y-Y, Huang Z-T, Li L, Wu M-H, Yu T, Koup RA, et al. Characterization of SARS-CoV-specific memory T cells from recovered individuals 4 years after infection. Arch Virol . 2009;154(7):1093-9.doi: 10.1007/s00705-009-0409-6 . PMID: 19526193.
  71. Tang F, Quan Y, Xin Z-T, Wrammert J, Ma M-J, Lv H, et al. Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: a six-year follow-up study.J Immunol . 2011;186(12):7264-8.doi: 10.4049/jimmunol.0903490. PMID: 21576510.
  72. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome.Lancet Respir Med. 2020;8(4):420-422.doi: 10.1016/S2213-2600(20)30076-X . PMID: 32085846.
  73. Williams AE, Chambers RC. The mercurial nature of neutrophils: still an enigma in ARDS?. Am J Physiol Lung Cell Mol Physiol . 2014;306(3):L217-L30.doi: 10.1152/ajplung.00311.2013 . PMID: 24318116.
  74. Cameron MJ, Bermejo-Martin JF, Danesh A, Muller MP, Kelvin DJ. Human immunopathogenesis of severe acute respiratory syndrome (SARS). Virus Res . 2008;133(1):13-9.doi: 10.1016/j.virusres.2007.02.014 . PMID: 17374415.
  75. Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol. 2020;38(1):1-9.doi: 10.12932/AP-200220-0772 . PMID: 32105090.
  76. Chan JF, Lau SK, To KK, Cheng VC, Woo PC, Yuen K-Y, et al. Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease. Clin Microbiol Rev . 2015;28(2):465-522.doi: 10.1128/CMR.00102-14 . PMID: 25810418.
  77. Pinto PG. Pilgrimage, commodities, and religious objectification: the making of transnational Shiism between Iran and Syria. Comparative Studies of South Asia, Africa and the Middle East. 2007;27(1):109-25.
  78. Gautret P, Benkouiten S, Al-Tawfiq JA, Memish ZA. Hajj-associated viral respiratory infections: a systematic review. Travel Med Infect Dis . 2016;14(2):92-109.doi: 10.1016/j.tmaid.2015.12.008 . PMID: 26781223.
  79. Yavarian J, Jandaghi NZS, Naseri M, Hemmati P, Dadras M, Gouya MM, et al. Influenza virus but not MERS coronavirus circulation in Iran, 2013–2016: Comparison between pilgrims and general population. Travel Med Infect Dis . 2018;21:51-5.doi: 10.1016/j.tmaid.2017.10.007 . PMID: 29031546.
  80. Al-Ghamdi SM, Akbar HO, Qari YA, Fathaldin OA, Al-Rashed RS. Pattern of admission to hospitals during muslim pilgrimage (Hajj). Saudi Med J . 2003;24(10):1073-6. PMID: 14578971.
  81. Hilgenfeld R, Peiris M. From SARS to MERS: 10 years of research on highly pathogenic human coronaviruses. Antiviral Res . 2013;100(1):286-95.doi: 10.1016/j.antiviral.2013.08.015 . PMID: 24012996.
  82. Al-Tawfiq JA, Zumla A, Memish ZA. Travel implications of emerging coronaviruses: SARS and MERS-CoV.Travel Med Infect Dis . 2014;12(5):422-8.doi: 10.1016/j.tmaid.2014.06.007 . PMID: 25047726.
  83. Hilgenfeld R. From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design. FEBS J . 2014;281(18):4085-96.doi: 10.1111/febs.12936 . PMID: 25039866.
  84. Stanhope MJ, Brown JR, Amrine-Madsen H. Evidence from the evolutionary analysis of nucleotide sequences for a recombinant history of SARS-CoV. Infection,Infect Genet Evol . 2004;4(1):15-9.doi: 10.1016/j.meegid.2003.10.001. PMID: 15019585.
  85. Zhang Z, Shen L, Gu X. Evolutionary dynamics of MERS-CoV: potential recombination, positive selection and transmission. Scientific Reports. 2016;6(1):1-10.
  86. Guarner J. Three Emerging Coronaviruses in Two Decades: The Story of SARS, MERS, and Now COVID-19.Am J Clin Pathol.  2020.doi: 10.1093%2Fajcp%2Faqaa029. PMID: 32053148.
  87. Arab-Mazar Z, Sah R, Rabaan AA, Dhama K, Rodriguez-Morales AJ. Mapping the incidence of the COVID-19 hotspot in Iran–Implications for Travellers. Travel Med Infect Dis . 2020;34:101630.doi: 10.1016/j.tmaid.2020.101630 . PMID: 32184130.
  88. WHO. Novel Coronaries (2019-Nov) situation report - 70. March 30, 2020.
  89. Abdi M. Coronavirus disease 2019 (COVID-19) outbreak in Iran; actions and problems. Infect Control Hosp Epidemiol . 2020;41(6):754-755.doi: 10.1017/ice.2020.86. PMID: 32192541.
  90. Takian A, Raoofi A, Kazempour-Ardebili S. COVID-19 battle during the toughest sanctions against Iran. The Lancet. 2020;395(10229):1035-1036.doi: 10.1016/S0140-6736(20)30668-1. PMID: 32199073.
  91. Umair M, Ikram A, Salman M, Badar N, Haider SA, Rehman Z, et al. Detection and whole-genome sequencing of SARS-CoV-2 B. 1.617. 2 and B. 1.351 variants of concern from Pakistan during the COVID-19 third wave. medRxiv. 2021.doi: 10.1101/2021.07.14.21259909.
  92. Gottlieb RL, Nirula A, Chen P, Boscia J, Heller B, Morris J, et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. Jama. 2021;325(7):632-644.doi: 10.1001/jama.2021.0202.
  93. Al-Mahruqi S, Al-Wahaibi A, Khan AL, Al-Jardani A, Asaf S, Alkindi H, et al. Molecular epidemiology of COVID-19 in Oman: A molecular and surveillance study for the early transmission of COVID-19 in the country.Int J Infect Dis . 2021;104:139-49.doi: 10.1016/j.ijid.2020.12.049. PMID: 33359061.